Venous Recanalization. Controlled
Chronic Venous Occlusions
Chronic Venous Occlusions are often difficult to cross requiring three to five guidewires and take between two to six hours to recanalize. VeinWay is developing Traversa, a novel medical device for controlled recanalization of chronic venous occlusions.
VeinWay provides physicians with a dedicated, purpose-built tool to create a pathway through a clogged vein such that physicians can easily restore blood flow through the vein to the heart. This tool is built to expand the physician’s ability to safely cross a variety of complicated blockages that were previously un-crossable, as well as shorten the time to cross.
VeinWay addresses an annual market of more than 1.7M Deep Vein Thrombosis (DVT) patients, half of which will return with Post Thrombotic Syndrome (PTS) within three to five years and 68% of those will have fully blocked veins. Traversa was developed by VeinWay as part of the MEDX Xelerator’s Entrepreneur-in-Residence program designed to promote breakthrough innovation. VeinWay is a portfolio company of the MEDX Xelerator, a medical device incubator backed by Boston Scientific, Sheba Medical Center, MEDX Ventures Group, Consensus Business Group (CBG), and West Pharmaceuticals.
Ben joined VeinWay as co-founder to lead our R&D program. With 10 years experience in medical device research and development. Ben brings to this position a significant track record in medical device innovation. His experience ranges from developing implants for minimally invasive spinal orthopedics (Nuvasive), basic academic research, to intravascular implant development in the field of structural heart. In his previous role as Senior Development Engineer at Restore Medical, Ben played a major role designing and developing the Contraband System, a nitinol based cardiovascular implant and subsequent transcatheter delivery system to treat CHF. He has taken products from the concept generation stage to clinical trials. He is listed on six issued and pending patents. He is a broadly experienced engineer skilled in nitinol and catheter design and has extensive knowledge of the start-up ecosystem. Ben holds a B.Sc. in Biomedical Engineering from the California Polytechnic State University (Cal Poly), a M.Sc. in Biotechnology Engineering from Ben Gurion University, and an MBA in Healthcare Innovation from Reichman University.